Table 2.
Blood parameters associated with viscosity, prothrombotic state, and arterial stiffness
| Training group (n = 23) | Control group (n = 23) | Training vs control groups at baseline | |||
|---|---|---|---|---|---|
| Baseline | Follow‐up | Baseline | Follow‐up | P value | |
| Erythrocytes, 106·μL−1 | 4.88 ± 0.4 | 4.84 ± 0.4 | 5.03 ± 0.3 | 4.94 ± 0.3 | .191 |
| Platelets, 103·μL−1 | 242 ± 52 | 238 ± 44 | 228 ± 39 | 223 ± 28 | .228 |
| Leukocytes, 103·μL−1 | 5.9 ± 1.3 | 6.5 ± 1.7 | 5.5 ± 1.1 | 5.9 ± 2.3 | .312 |
| Fibrinogen, μmol·L−1 | 8.4 ± 2.0 | 8.2 ± 1.3 | 8.3 ± 2.3 | 8.1 ± 1.1 | .906 |
| hs‐CRP, ηmol·L−1 | 28 ± 21 | 28 ± 21 | 22 ± 18 | 25 ± 22 | .278 |
| Insulin, ρmol·L−1 | 87 ± 32 | 82 ± 36 | 91 ± 36 | 93 ± 38 | .725 |
| Total cholesterol, mmol·L−1 | 4.8 ± 0.8 | 4.7 ± 1.0 | 4.7 ± 0.8 | 4.9 ± 0.7 | .758 |
| LDL‐C, mmol·L−1 | 3.2 ± 0.8 | 3.0 ± 0.9 | 3.1 ± 0.8 | 3.2 ± 0.5 | .831 |
Abbreviations: hs‐CRP, high‐sensitivity C‐reactive protein; LDL‐C, low‐density lipoprotein cholesterol.
Data are presented as mean ± standard deviation for 46 patients with metabolic syndrome divided into training and control groups.